Friday, July 17, 2026

pharma · Cystic Fibrosis (CF) · Accidental Hypothermia · SION

Sionna Therapeutics

Sionna Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker SION. Primary therapeutic focus areas include Cystic Fibrosis (CF), Accidental Hypothermia, Bleeding, End-stage Ki

Boston, USA HQ
2019 Founded
74 Employees
Public company Type
SION · NYSE Ticker
Company details
Status
Public
HQ
Boston, USA
Founded
2019
Employees
74
Programs
5
Drugs
3
Patents
0
Clinical program

Polyamide HD membrane

Phase 3 · other · End-stage Kidney Disease

Polyamide HD membrane for End-stage Kidney Disease is a Phase 3 program (other) at Sionna Therapeutics with 1 ClinicalTrials.gov record(s).

Internal code HighCO Hemo study

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Sionna Therapeutics
Phase
Phase 3
Modality
other
Indication
End-stage Kidney Disease
Status
active
Trials
1

Clinical trials